Literature DB >> 27429034

Prognostic Significance of the Location of Lymph Node Metastases in Patients With Adenocarcinoma of the Distal Esophagus or Gastroesophageal Junction.

Maarten C J Anderegg1, Sjoerd M Lagarde, Vamshi P Jagadesham, Suzanne S Gisbertz, Arul Immanuel, Sybren L Meijer, Maarten C C M Hulshof, Jacques J G H M Bergman, Hanneke W M van Laarhoven, S Michael Griffin, Mark I van Berge Henegouwen.   

Abstract

OBJECTIVE: To identify the prognostic significance of the location of lymph node metastases in patients with esophageal or gastroesophageal junction (GEJ) adenocarcinoma treated with neoadjuvant therapy followed by esophagectomy.
BACKGROUND: Detection of lymph node metastases in the upper mediastinum and around the celiac trunk after neoadjuvant therapy and resection does not alter the TNM classification of esophageal carcinoma. The impact of these distant lymph node metastases on survival remains unclear.
METHODS: Between March 2003 and September 2013, 479 consecutive patients with adenocarcinoma of the distal esophagus or GEJ who underwent transthoracic esophagectomy with en bloc 2-field lymphadenectomy after neoadjuvant therapy were included, and survival was analyzed according to the location of positive lymph nodes in the resection specimen.
RESULTS: Two hundred fifty-three patients had nodal metastases in the resection specimen. Of these patients, 92 patients had metastases in locoregional nodes, 114 patients in truncal nodes, 21 patients in the proximal field of the chest, and 26 patients had both positive truncal and proximal field nodes. Median disease-free survival was 170 months in the absence of nodal metastases, 35 months for metastases limited to locoregional nodes, 16 months for positive truncal nodes, 15 months for positive nodes in the proximal field, and 8 months for nodal metastases in both truncal and the proximal field. On multivariate analysis, location of lymph node metastases was independently associated with survival.
CONCLUSIONS: Location of lymph node metastases is an independent predictor for survival. Relatively distant lymph node metastases along the celiac axis and/or the proximal field have a negative impact on survival. Location of lymph node metastases should therefore be considered in future staging systems of esophageal and GEJ adenocarcinoma.

Entities:  

Mesh:

Year:  2016        PMID: 27429034     DOI: 10.1097/SLA.0000000000001767

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  15 in total

1.  Extracapsular lymph node involvement in patients with esophageal cancer treated with neoadjuvant chemoradiation therapy followed by surgery: the closer you look, the less you see.

Authors:  Yin-Kai Chao
Journal:  J Thorac Dis       Date:  2017-11       Impact factor: 2.895

Review 2.  The extent of lymphadenectomy in esophageal resection for cancer should be standardized.

Authors:  Eliza R C Hagens; Mark I van Berge Henegouwen; Miguel A Cuesta; Suzanne S Gisbertz
Journal:  J Thorac Dis       Date:  2017-07       Impact factor: 2.895

3.  Surgeon Assessment of Gastric Cancer Lymph Node Specimens with a Video of Technique.

Authors:  Naruhiko Ikoma; Jeannelyn S Estrella; Wayne L Hofstetter; Jaffer A Ajani; Keith F Fournier; Paul F Mansfield; John M Skibber; Brian D Badgwell
Journal:  J Gastrointest Surg       Date:  2018-07-27       Impact factor: 3.452

4.  Consensus statement of the Hellenic and Cypriot Oesophageal Cancer Study Group on the diagnosis, staging and management of oesophageal cancer.

Authors:  Andreas Fountoulakis; John Souglakos; Louiza Vini; Gerasimos N Douridas; Anna Koumarianou; Panteleimon Kountourakis; Christos Agalianos; Andreas Alexandrou; Christos Dervenis; Sofia Gourtsoyianni; Nikolaos Gouvas; Maria-Angeliki Kalogeridi; Georgia Levidou; Theodoros Liakakos; Joseph Sgouros; Spiros N Sgouros; Charikleia Triantopoulou; Evangelos Xynos
Journal:  Updates Surg       Date:  2019-12-02

5.  Supraclavicular and celiac metastases in squamous cell carcinoma of the middle thoracic esophagus.

Authors:  Akihiko Okamura; Masayuki Watanabe; Ryotaro Kozuki; Tasuku Toihata; Masami Yuda; Yu Imamura; Shinji Mine
Journal:  Langenbecks Arch Surg       Date:  2018-10-25       Impact factor: 3.445

6.  Extended thoracic lymph node dissection in robotic-assisted minimal invasive esophagectomy (RAMIE) for patients with superior mediastinal lymph node metastasis.

Authors:  Sylvia van der Horst; Michiel F G de Maat; Pieter C van der Sluis; Jelle P Ruurda; Richard van Hillegersberg
Journal:  Ann Cardiothorac Surg       Date:  2019-03

7.  Population Registry of Esophageal and Stomach Tumours in Ontario (PRESTO): protocol for a multicentre clinical and pathological database including 25 000 patients.

Authors:  Vaibhav Gupta; Jordan Levy; Catherine Allen-Ayodabo; Elmira Amirazodi; Laura Davis; Qing Li; Alyson Mahar; Natalie G Coburn
Journal:  BMJ Open       Date:  2020-05-30       Impact factor: 2.692

8.  Optimal Extent of Transhiatal Gastrectomy and Lymphadenectomy for the Stomach-Predominant Adenocarcinoma of Esophagogastric Junction: Retrospective Single-Institution Study in China.

Authors:  Baoyu Zhao; Zhenzhan Zhang; Debin Mo; Yiming Lu; Yanfeng Hu; Jiang Yu; Hao Liu; Guoxin Li
Journal:  Front Oncol       Date:  2019-01-21       Impact factor: 6.244

9.  Disseminated tumour cells with highly aberrant genomes are linked to poor prognosis in operable oesophageal adenocarcinoma.

Authors:  Sarah Schumacher; Christoph Bartenhagen; Martin Hoffmann; Daniel Will; Johannes C Fischer; Stephan E Baldus; Christian Vay; Georg Fluegen; Levent Dizdar; Daniel Vallböhmer; Christoph A Klein; Wolfram T Knoefel; Nikolas H Stoecklein; Birte Möhlendick
Journal:  Br J Cancer       Date:  2017-07-20       Impact factor: 7.640

10.  Clinical significance of esophageal invasion length for the prediction of mediastinal lymph node metastasis in Siewert type II adenocarcinoma: A retrospective single-institution study.

Authors:  Kazuo Koyanagi; Fumihiko Kato; Jun Kanamori; Hiroyuki Daiko; Soji Ozawa; Yuji Tachimori
Journal:  Ann Gastroenterol Surg       Date:  2018-04-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.